TETSUO ASHIZAWA to Double-Blind Method
This is a "connection" page, showing publications TETSUO ASHIZAWA has written about Double-Blind Method.
Connection Strength
0.055
-
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial. Lancet Neurol. 2023 03; 22(3):218-228.
Score: 0.039
-
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010 Mar 15; 25(4):426-32.
Score: 0.016